Deerfield Management Company, L.P. (Series C) Nurix Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$12.02 - $21.3 $132,099 - $234,087	10,990 Added 66.54%	27,507 $574,000
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $6,208 - $12,512	799 Added 5.08%	16,517 $242,000
Q4 2023 Feb 14, 2024	BUY	$4.25 - $10.71 $66,801 - $168,339	15,718 New	15,718 $162,000

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

Black Rock Inc. New York, NY

6.82M
Shares

$151 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

4.28M
Shares

$94.7 Million
6.28% of portfolio
Vanguard Group Inc Valley Forge, PA

4.01M
Shares

$88.7 Million
0.0% of portfolio
Baker Bros. Advisors LP New York, NY

3.88M
Shares

$85.8 Million
0.93% of portfolio
Deep Track Capital, LP Greenwich, CT

3.87M
Shares

$85.5 Million
3.2% of portfolio

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.04B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account